Jieying Liu

Introduction

Jieying Liu is an accomplished inventor based in Shanghai, China, known for her significant contributions to the field of biologics. With a total of three patents to her name, she has demonstrated a strong commitment to advancing therapeutic solutions through innovative scientific research.

Latest Patents

Jieying Liu's recent work includes the development of anti-CD19 antibodies and bispecific CD3/CD19 polypeptide complexes. The anti-CD19 antibodies patent provides detailed descriptions of these antibodies or antigen-binding fragments, alongside isolated polynucleotides encoding them and their pharmaceutical applications. Her patent on bispecific CD3/CD19 polypeptide complexes outlines a unique polypeptide complex that incorporates two antigen-binding moieties, along with various methods for its production and application in treating related diseases or disorders.

Career Highlights

Jieying is currently associated with Wuxi Biologics Ireland Limited, a company noted for its impactful work in biopharmaceutical development. Her role at Wuxi Biologics has allowed her to play a pivotal part in the advancement of therapeutic antibodies aimed at improving cancer treatment.

Collaborations

Throughout her career, Jieying Liu has collaborated with notable colleagues, including Jing Li, who contributes to the synergy of innovative ideas and solutions within their research projects. These collaborations reflect the importance of teamwork in driving scientific advancements and achieving collective goals in the field.

Conclusion

Jieying Liu's inventive achievements and her commitment to research have significantly influenced the biologics landscape. Her ongoing work, alongside her collaborations, stands as a testament to her prowess as an inventor and her dedication to creating innovative therapies that may improve patient outcomes in the medical field.